Rapidly dividing tumor and normal cells

The term "Rapidly dividing tumor and normal cells" refers to a physiological state of high mitotic activity rather than a specific molecular target such as a protein, receptor, or enzyme. In the context of oncology, traditional cytotoxic chemotherapy is designed to exploit the rapid proliferation of malignant cells by interfering with DNA replication or chromosome segregation during mitosis (National Cancer Institute, 2023). However, these therapeutic agents lack specificity and also target healthy, high-turnover tissues, including the bone marrow, intestinal epithelium, and hair follicles (StatPearls, 2023). This non-selective destruction of normal proliferating cells is the primary cause of the systemic toxicities associated with conventional cancer treatment, such as neutropenia and mucositis (American Cancer Society, 2024). Because this entry describes a broad cellular population across multiple organ systems rather than a discrete biochemical entity, it is classified as an incorrect therapeutic target for precision medicine. Modern drug development has largely shifted away from this broad approach toward targeting specific oncogenic drivers or cell-surface antigens to improve the therapeutic index and spare normal tissues.

Other names

Proliferating cellsMitotically active cellsHigh-turnover cells

Inhibition of DNA synthesis (antimetabolites), DNA cross-linking (alkylating agents), stabilization or destabilization of microtubules (taxanes/vinca alkaloids), and inhibition of topoisomerases to induce apoptosis in actively dividing cells.